Needham & Company
-
Needham Reiterates Buy Rating on RxSight Inc. (RXST)
-
Needham Reiterates Buy Rating on RxSight Inc. (RXST)
-
RxSight Inc. (RXST) PT Raised to $66 at Needham, Added to Conviction List
-
RxSight Inc. (RXST) PT Lowered to $54 at Needham
-
RxSight Inc. (RXST) PT Raised to $75 at Needham
-
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
-
RxSight Inc. (RXST) PT Raised to $64 at Needham, '4Q23 Showed Solid Revenue Growth And Margin Improvement'
-
RxSight, Inc. to Present at the Needham Healthcare Conference
-
RxSight, Inc. to Present at the Needham Healthcare Conference
-
UPDATE: Needham & Company Starts RxSight Inc. (RXST) at Buy
-
RxSight, Inc. to Present at the Needham Virtual Healthcare Conference
-
RxSight, Inc. to Present at the Needham Virtual Healthcare Conference

